Merck is no longer as involved in the hepatitis C market.
- Merck & Co. has discontinued the development of two investigational combination regimens that were in testing for the treatment of chronic hepatitis C, citing its review of Phase 2 efficacy data and the current status of the marketplace.
- The two regimens being dropped are MK-3682B and MK-3682C, both of which contained the experimental uprifosbuvir. Merck said it will maintain its already-marketed hepatitis C offering Zepatier, a fixed dose combination of elbasvir and grazoprevir.
- This move doesn’t come as entirely unexpected. In February, Merck wrote down the value of hepatitis C drug uprifosbuvir by $2.9 billion, recognizing the drugs’ reduced commercial potential given the competitive nature of the market.
Read full article: Merck drops hep C programs in ‘strategic decision’ | BioPharma Dive
|Read Full Article: Merck drops hep C programs in ‘strategic decision’ | BioPharma Dive|